An uncommon phenotype of poor inducibility of CYP1A1 in human lung is not ascribable to polymorphisms in the AHR, ARNT, or CYP1A1 genes

被引:33
作者
Anttila, S
Lei, XD
Elovaara, E
Karjalainen, A
Sun, WM
Vainio, H
Hankinson, O
机构
[1] Univ Calif Los Angeles, Ctr Hlth Sci, Dept Pathol & Lab Med, Los Angeles, CA 90095 USA
[2] Univ Calif Los Angeles, Johnson Comprehens Canc Ctr, Los Angeles, CA USA
[3] Int Agcy Res Canc, F-69372 Lyon, France
[4] Finnish Inst Occupat Hlth, Helsinki, Finland
来源
PHARMACOGENETICS | 2000年 / 10卷 / 08期
关键词
AHR; ARNT; CYP1A1; polymorphisms;
D O I
10.1097/00008571-200011000-00008
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Cigarette smoking can induce CYP1A1 in the lung, Induction requires the aryl hydrocarbon receptor (AHR) and aryl hydrocarbon receptor nuclear translocator (ARNT) proteins. Lung samples from seven of 75 Finnish patients who smoked until the time of surgery exhibited absent or low levels of CYP1A1 protein, mRNA and enzymatic activity, suggesting that these individuals might be genetically non or poorly inducible for CYP1A1. All seven lung samples expressed normal levels of AHR mRNA and ARNT mRNA, indicating that they did not carry inactivating polymorphisms in the 5' upstream regulatory regions of these genes, Sequencing of cDNAs encompassing the complete coding regions of AHR and ARNT identified a previously known codon 554 polymorphism in AHR, which was present in the homozygous state in one individual. This polymorphism, which leads to an amino acid substitution, has previously been reported either to have no effect or to enhance CYP1A1 induction. Previously unreported silent single nucleotide polymorphisms were identified in codon 44 of AHR and codon 189 of ARNT. 1500 bp of genomic sequence from the 5' upstream regulatory sequence of the CYP1A1 gene was also sequenced in the non-inducible individuals. A nucleotide substitution polymorphism at position -459 was detected in the heterozygous state in two individuals. This polymorphic site does not reside in any known regulatory sequence, The complete CYP1A1 coding sequence and intron/exon boundaries were then sequenced. None of the non or poorly inducible individuals exhibited any polymorphisms, either homozygous or heterozygous compared to representative inducible individuals or the previously published CYP1A1 sequence. Thus, no polymorphisms in the AHR, ARNT or CYP1A1 genes were identified that could be responsible for the non/low inducibility phenotype observed. Pharmacogenetics 10:741-751 (C) 2000 Lippincott Williams & Wilkins.
引用
收藏
页码:741 / 751
页数:11
相关论文
共 49 条
  • [41] Saarikoski ST, 1998, INT J CANCER, V77, P33, DOI 10.1002/(SICI)1097-0215(19980703)77:1<33::AID-IJC7>3.0.CO
  • [42] 2-0
  • [43] Characterization of a murine Ahr null allele: Involvement of the Ah receptor in hepatic growth and development
    Schmidt, JV
    Su, GHT
    Reddy, JK
    Simon, MC
    Bradfield, CA
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1996, 93 (13) : 6731 - 6736
  • [44] Shimada T, 1996, CANCER RES, V56, P2979
  • [45] THE ROLE OF 12-CDNA-EXPRESSED HUMAN, RODENT, AND RABBIT CYTOCHROMES-P450 IN THE METABOLISM OF BENZO[A]PYRENE AND BENZO[A]PYRENE TRANS-7,8-DIHYDRODIOL
    SHOU, MG
    KORZEKWA, KR
    CRESPI, CL
    GONZALEZ, FJ
    GELBOIN, HV
    [J]. MOLECULAR CARCINOGENESIS, 1994, 10 (03) : 159 - 168
  • [46] Variation in induced CYP1A1 levels:: relationship to CYP1A1, Ah receptor and GSTM1 polymorphisms
    Smart, J
    Daly, AK
    [J]. PHARMACOGENETICS, 2000, 10 (01): : 11 - 24
  • [47] A mutation in the aryl hydrocarbon receptor (AHR) in a cultured mammalian cell line identifies a novel region of AHR that affects DNA binding
    Sun, WM
    Zhang, JZ
    Hankinson, O
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 1997, 272 (50) : 31845 - 31854
  • [48] Silencing of CYP1A1 expression in rabbits by DNA methylation
    Takahashi, Y
    Suzuki, C
    Kamataki, T
    [J]. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1998, 247 (02) : 383 - 386
  • [49] Zhang JZ, 1996, MOL PHARMACOL, V50, P1454